Vinita Gupta, Lupin CEO, Named to the 2026 CNBC Changemakers List of Women Transforming Business

Global pharmaceutical leader, Lupin Limited announced that CEO Vinita Gupta was recognized on the CNBC Changemakers list of Women Transforming Business. Each year, this prestigious list honors female leaders who are redefining industries, breaking barriers, and driving lasting change across various business sectors.

"I am honored to be recognized as a CNBC Changemaker and listed amongst such extraordinary leaders who are driving significant change and impact," said Vinita Gupta, CEO, Lupin. "This recognition reflects not only my own journey, but the shared dedication of everyone at Lupin who works each day to help transform hope into healing. I truly believe that meaningful change occurs when purpose is matched by execution. I extend my congratulations to all the other honorees."

Vinita built Lupin's U.S. business from the ground up. During her tenure as CEO, the company grew into the third-largest generic medicine supplier to the U.S. and the world's seventh-largest pharmaceutical company by volume. Under her leadership, Lupin continues to expand its impact on affordable medicine, complex generics, inhalation and biosimilars. In late 2025, Lupin gained FDA approval for its first biosimilar Pegfilgrastim, marking a pivotal step in Lupin's ongoing commitment to providing high-quality, affordable medicines to U.S. patients.